Use of serotonergic antidepressants and St John's wort in older Australians: A population-based cohort study

Australasian Psychiatry

Volumn 21, Issue 3, 2013, Pages 262-266

  Rahman, Syed Ziaur ^a,b   Basilakis, Jim ^b   Rahmadi, Anton ^b   Lujic, Sanja ^b   Musgrave, Ian ^c   Jorm, Louisa ^b   Hay, Phillipa ^b,d   Munch, Gerald ^b  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b UNIVERSITY OF WESTERN SYDNEY   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d JAMES COOK UNIVERSITY   (Australia)

Author keywords

Antidepressants; Drug interactions; Hypericum perforatum; Selective serotonin reuptake inhibitors; Serotonin norepinephrine reuptake inhibitors; St John's wort

Indexed keywords

HYPERICUM PERFORATUM EXTRACT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ADULT; AGED; ANXIETY; ARTICLE; AUSTRALIA; COHORT ANALYSIS; COMMUNITY SAMPLE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PREVALENCE; QUESTIONNAIRE; SELF REPORT; SEX DIFFERENCE; TREATMENT DURATION;

ANTIDEPRESSANTS; DRUG INTERACTIONS; HYPERICUM PERFORATUM; SELECTIVE SEROTONIN REUPTAKE INHIBITORS; SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS; ST JOHN'S WORT;

AGE DISTRIBUTION; AGED; ANTIDEPRESSIVE AGENTS; ANXIETY; AUSTRALIA; COHORT STUDIES; DEPRESSIVE DISORDER; DRUG INTERACTIONS; FEMALE; HUMANS; HYPERICUM; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT PREPARATIONS; QUESTIONNAIRES; SEROTONIN SYNDROME; SEROTONIN UPTAKE INHIBITORS; SEX DISTRIBUTION;

EID: 84880738311     PISSN: 10398562     EISSN: 14401665     Source Type: Journal    
DOI: 10.1177/1039856213475681     Document Type: Article

References (29)

1. Statistics ABO. National survey of mental health and wellbeing: Summary of results. In: Statistics ABO (ed). 2007, pp. 10.
2. O'Connor DW. Do older Australians truly have low rates of anxiety and depression? A critique of the 1997 national survey of mental health and wellbeing. Aust New Zeal J Psychiatr 2006; 40: 623-631.
3. Baldwin RA. Mood disorders: Depressive disorders. In: Jacoby R, Oppenheimer C, Dening T, et al. (eds). Oxford textbook of old age psychiatry. Oxford: Oxford University Press, 2008, pp.529-556.
4. Cummings SM. Predictors of psychological well-being among assisted-living residents. Health Soc Work 2002; 27: 293-302.
5. Fugh-Berman A. Herb-drug interactions. Lancet 2000; 355: 134-138.
6. Muller WE, Singer A, Wonnemann M, et al. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry 1998; 31 Suppl 1: 16-21.
7. Barnes J, Anderson LA and Phillipson JD. St John's wort (Hypericum perforatum L.): A review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53: 583-600.
8. Xue CC, Zhang AL, Lin V, et al. Complementary and alternative medicine use in Australia: A national population-based survey. J Alternative Compl Med 2007; 13: 643-650.
9. Martin-Facklam M, Rieger K, Riedel KD, et al. Undeclared exposure to St. John's wort in hospitalized patients. Br J Clin Pharmacol 2004; 58: 437-441.
10. Borrelli F and Izzo AA. Herb-drug interactions with St John's wort (Hypericum perforatum): An update on clinical observations. AAPS J 2009; 11: 710-727.
11. Izzo AA. Drug interactions with St. John's wort (Hypericum perforatum): A review of the clinical evidence. Int J Clin Pharmacol Ther 2004; 42: 139-148.
12. Izzo AA and Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs 2001; 61: 2163-2175.
13. Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004; 18: 262-276.
14. Banks E, Redman S, Jorm L, et al. Cohort profile: The 45 and up study. Int J Epidemiol 2008; 37: 941-947.
15. Therapeutic guidelines: Psychotropic. In: Group PE (ed). Version 6. Melbourne: Therapeutic Guidelines Limited, 2008, pp. 1-325.
16. Rossi S. Australian medicines handbook. Adelaide: Australian Medicines Handbook Pty Ltd. 2007.
17. Côté RA and College of American Pathologists. SNOMED International: The systematized nomenclature of human and veterinary medicine. 3rd ed. Northfield, Illinois; Schaumberg, Illinois: College of American Pathologists; American Veterinary Medical Association, 1993.
18. WHO. Introduction to drug utilization research 2003. In: WHO international working group for drug statistics methodology WCCfDSM, WHO collaborating centre for drug utilization research and clinical pharmacological services. Oslo: World Health Organization, pp. 1-48.
19. Kesava Reddy G. Glucose-mediated in vitro glycation modulates biomechanical integrity of the soft tissues but not hard tissues. J Orthop Res 2003; 21: 738-743.
20. Hauser RA and Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997; 12: 756-759.
21. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-880.
22. Zhang Y, Chow V, Vitry AI, et al. Antidepressant use and depressive symptomatology among older people from the Australian longitudinal study of ageing. Int Psychogeriatr 2010; 22: 437-444.
23. Hollingworth SA, Lie DC, Siskind DJ, et al. Psychiatric drug prescribing in elderly Australians: Time for action. Aust New Zeal J Psychiatr 2011; 45: 705-708.
24. Pratt LA, Brody DJ and Gu Q. Antidepressant use in persons aged 12 and over: United States, 2005-2008. NCHS Data Brief 2011: 76: 1-8.
25. Poluzzi E, Motola D, Silvani C, et al. Prescriptions of antidepressants in primary care in Italy: Pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement. Eur J Clin Pharmacol 2004; 59: 825-831.
26. Johannessen H, von Bornemann Hjelmborg J, Pasquarelli E, et al. Prevalence in the use of complementary medicine among cancer patients in Tuscany, Italy. Tumori 2008; 94: 406-410.
27. Schernhammer ES, Haidinger G, Waldhor T, et al. Attitudes about the use of complementary and alternative medicine in cancer treatment. J Alternative Compl Med 2009; 15: 1115-1120.
28. Parslow RA and Jorm AF. Use of prescription medications and complementary and alternative medicines to treat depressive and anxiety symptoms: Results from a community sample. J Affect Disord 2004; 82: 77-84.
29. Sussman N. Medical complications of SSRI and SNRI treatment. Prim Psychiatr 2008; 15: 37-41.